18, June 2020
Biya regime implements new e-customs system 0
Cameroon has rolled out the Cameroon Customs Information System (CAMCIS), a fully-automated electronic customs clearance system to reduce face-to-face engagement amid the COVID-19 pandemic.
CAMCIS was built by Korean engineers and is the result of a 12-year-old public-private partnership said Edwin Fongod Nuvaga, Director General of Customs.
The system is modelled on UNI-PASS, used by the Korea Customs Service, and designed to handle large volumes of data, fully automate processes and procedures as part of a paperless system.
According to customs officials CAMCIS replaces the Automated System for Customs Data (ASYCUDA ++) which has been in use in Cameroon since 2007.
Speaking at the recent launch of CAMCIS, Louis Paul Motaze, Cameroon’s Minister of Finance said the new system will significantly improve the business environment and spur profitability in the private sector by saving time and money.
The Minister highlighted the system’s operational speed, and said it will simplify import and export procedures and offer more security in the collection of customs revenue.
Customs duties and taxes are a key source of income for the government and in 2019 accounted for 14.3%.
“It is estimated that with CAMCIS, we would save a maximum number of days for our operations. Also, it will be possible to carry out customs clearance operations within one day after the validation of papers,” reads a statement issued by Cameroon Customs.
Séraphin Deffo Deffo, Chief Information Officer of CAMCIS, said the new system will guarantee traceability of all transaction, prevent fraud and corruption, enhance proper control of goods on transit, fasten procurement of customs duties and taxes, amongst others.
CAMCIS can be accessed and operated remotely using any digital device with a browser and an internet connection. It has three portals accessible to customs administration, economic operators and the general public.
Source: itweb.Africa


















18, June 2020
WHO halts hydroxychloroquine trial for Covid-19 over lack of proven benefit 0
The World Health Organization said on Wednesday that testing of the malaria drug hydroxychloroquine in its large multi-country trial of treatments for COVID-19 patients had been halted after new data and studies showed no benefit.
WHO expert Ana Maria Henao-Restrepo said investigators leading the so-called Solidarity Trial testing the drug – which had been promoted by U.S. President Donald Trump – had reviewed recent evidence and decided to stop recruiting new patients.
“After deliberation, they have concluded that the hydroxychloroquine arm will be stopped from the Solidarity Trial,” Henao-Restrepo told a media briefing.
In a statement issued later on Wednesday, the WHO said the decision was based on evidence from the Solidarity Trial itself, as well as from a UK-led trial that had found the drug did not help COVID-19 patients, and from a review of other evidence on hydroxychloroquine.
Data from those studies “showed that hydroxychloroquine does not result in the reduction of mortality of hospitalised COVID-19 patients,” the WHO statement said.
It said Solidarity Trial investigators would not add any more patients to the hydroxychloroquine arm.
But it added: “Patients who had already started hydroxychloroquine but who have not yet finished their course in the trial may complete their course or stop at the discretion of the supervising physician.”
Data from a UK-led clinical trial known as the Recovery trial found last week that the anti-malaria drug showed no benefit for patients with COVID-19.
The U.S. Food and Drug Administration on Monday revoked its emergency use authorization for hydroxychloroquine to treat COVID-19, saying it was no longer reasonable to believe that hydroxychloroquine and the related drug chloroquine would be effective in treating the disease.
Source: REUTERS